The SonoScape S8 is leading the charge of transportable high resolution ultrasound instruments with advanced M-mode imaging technologies capable of measuring:

• Cardiac Output
• Heart Rate
• LVEDD and LVESD
• PWT and SWT

Superior quality 4D cardiac imaging is now accessible and affordable at PhysioGenix, a world leader in preclinical research services.

For more information please contact us as www.physiogenix.com.

Milwaukee, WI (PRWEB) March 23, 2011 – PhysioGenix, already a leader in customer focused contract research, expanded their research facilities, capabilities and research models in 2010. “We experienced tremendous growth in 2010 and anticipate additional growth in 2011,” stated PhysioGenix’s Director of Sales Darin Evans.

PhysioGenix was a winner of Companies to Watch for 2010 by the Wisconsin Entrepreneur Network (WEN) with support from the Wisconsin Department of Commerce and the Division of Entrepreneurship and Economic Development at the University of Wisconsin-Extension in association with the Edward Lowe Foundation to celebrate second-stage entrepreneurial companies. PhysioGenix proved that they deserved the award when they posted record high sales numbers while expanding the company during an economic recession.

One of the largest changes in 2010 was the completion of a new facility in December. The new facility has allowed PhysioGenix to streamline processes and cut costs, which the company is passing onto their clients. Furthermore, the new facilities enabled PhysioGenix to expand their capabilities and research models.

PhysioGenix is known for their excellence in diabetes and metabolic research. During the course of 2010, PhysioGenix expanded their capabilities to include cardiovascular studies. The company saw success over the course of the year and began to build a name for themselves in the field prompting further addition of new internal capabilities such as cardiovascular ultrasound imaging.

Last year also saw PhysioGenix continue their expansion of research models. Previously the company focused on rat studies. In 2010 PhysioGenix brought on a mouse expert and began selling mouse studies. PhysioGenix’s success with multiple mouse models has lead the company to dedicate an entire portion of their new lab facilities to mouse research.

PhysioGenix focuses on providing better customer service, coupled with accurate and reliable lab data that they present to their clients in near-real time. CEO Dr. Brian Curry explains, “Clients we work with come back for numerous studies because they state PhysioGenix provides a level of communication that is difficult to find with other preclinical CROs.”

Although 2010 was an enormous success for PhysioGenix, Dr. Curry is focused on the future, “We are positioned very well to take advantage of an improved economic environment in 2011 and this translates directly into more jobs, which is a good thing for all of us.”

To learn more about PhysioGenix go to www.physiogenix.com.

Milwaukee, WI (PRWEB) March 20, 2011 — PhysioGenix has donated to the American Red Cross to help provide relief for the recent earthquake and tsunami victims. PhysioGenix has been in e-mail contact with several of their Japanese colleagues who have informed them that they and their families are all right. “It feels like we need to do more than check in on our colleagues and end an e-mail with ‘you are in our thoughts and prayers” said PhysioGenix’s CEO Brian Curry.

Japan was struck with an awful disaster at the end of last week with a 9.0 MW earthquake devastating many areas. It was the largest earthquake in the history of Japan and the fourth largest ever in the world. The aftermath of the earthquake continues to wreck Japan as they have been plagued with over a hundred aftershocks, a 6.6 MW earthquake, tsunamis, explosions and state of emergency issues with their nuclear power plants. Japanese Prime Minister Naoto Kan said that “in the 65 years after the end of World War II, this is the toughest and the most difficult crisis for Japan.”

“We have many scientific colleagues and clients from Japan and felt it was necessary to do what we could,” said Dr. Curry. “We are very privileged to work everyday with our clients on treatments of diabetes and cardiovascular disorders that will eventually help mankind.” Some of the drug compounds PhysioGenix tests may take another 10 years before commercialization but the payoff to mankind is well worth the wait. The employees at PhysioGenix are patient and do not mind the long timeline because of high payoff, “however, sometimes you feel the need to help now,” stated Yvette Harrington, Science Liaison for PhysioGenix. The company felt this was one of those times. “Many of our employees have stood at the lab bench with international graduate students, post-docs and professors over the course of their careers and education. We have made good friends and conducted great scientific research together and knew that we could not sit idly by while Japan was dealing with a disaster of this magnitude,” said Dr. Curry.

PhysioGenix likes to live by a phrase they picked up from Mavericks at Work by Taylor and LaBarre, which is ‘build a company that works and work for a company that matters.’ The employees at PhysioGenix agree, helping the Japanese victims matters. “When you donate to quality organizations such as the American Red Cross you know that your money is directly helping people today,” said Dr. Curry. PhysioGenix would also like to ask other scientific based companies to follow suite.

The study design tool is aimed at gathering vital information for a preclinical rodent study in a matter of minutes. Traditionally within the industry, gathering this information could take weeks of planning, phone calls, and emails. Now with this new study design tool, planning can be completed online in a matter of minutes. Researchers are free to use the tool as much as they would like. Throughout the process, PhysioGenix can be called upon for expertise in designing your specific preclinical study. PhysioGenix has the network of experts, that combined with the study design tool, can help make the planning stages easier, and faster.

Brian Curry, CEO of PhysioGenix says, “Our study design tool is the first of its kind in the preclinical research space. We are eager for our clients to utilize the tool for all their preclinical planning.” By allowing prospective clients to use this tool, PhysioGenix hopes to speed up the preclinical planning and execution phases of drug development – ultimately saving companies money. The tool also allows PhysioGenix to respond to a clients study submission in less than 24 hours – often with a proposal.

The study design tool is currently in beta, and PhysioGenix is seeking forward thinking scientists and researchers to use the tool in this phase. Future versions of the tool will have automatic recommendations from PhysioGenix, yearly planning tools, immediate quote responses, drag and drop functionality, and more!

Please visit our website to sign up at http://physiogenix.com/sign-up and learn how to start using this free online study design tool.

About the company
A world-leader in complex chronic disease research services and solutions. Our goal is to be the world-leader in research services for organizations conducting studies involving therapeutics and medical devices for complex chronic diseases. Through our in-house capabilities and partnerships with outside experts, we seek to deliver the most comprehensive suite of solutions in our fields of expertise.

Our services. We provide a full range of drug research services. From study design to reporting, our clients have come to appreciate our time sensitive, client focused services. Our capabilities include pharmacodynamics, pharmacokinetics, safety pharmacology, drug metabolism, phenotyping, specialized blood pressure monitoring, and bioanalytical services.

Like most companies to reach the point of becoming worthy of such an award, PhysioGenix first needed to overcome two major obstacles.

The pharmaceutical industry is very regionally concentrated on the West and East coast. Executive Vice President Greg Meier explains, “geography is becoming less of an issue in business because of the proliferation and leveraging of technology.” 80% of PhysioGenix’s clients are from the West coast and in the last two years the international business they have received has grown significantly. Dr. Curry says that, “At no point has distance been a hindrance on our business, in fact, every company that we do business with chooses to return for additional projects.”

“One of the strengths of being located in Milwaukee, Wisconsin compared to other areas in the nation is the access to a number of well trained scientists and the close proximity of numerous universities, specifically the Medical College of Wisconsin, Marquette University, and the University of Wisconsin-Milwaukee,” said Dr. Curry, “We have some of the best scientists and technical staff around.”

Beyond the hurdles of reorganization, PhysioGenix had to deal with the poor economy, which has had both a positive and negative effect on their industry. The weaker economy over the past year has forced pharmaceutical companies to reduce staff and increase outsourcing. However, as the market has grown, so has the competition. Fortunately, PhysioGenix has thrived in this new environment, leading to record sales in 2009, the highest the company has seen in its 10 years in business.

With the tremendous foresight in the past two years and the ambitious plans for the next year it is no wonder why PhysioGenix won an award for being ‘worth watching.’ PhysioGenix’s goal is to never rest on its laurels but instead continually strive to innovate, contain costs, and collaborate with industry leaders. To achieve this goal, Director of Operations Darin Evans says that PhysioGenix will be using new preclinical research models and expanding into medical device testing in 2010. Dr. Curry is excited by the prospect of 2010, “With our sales and marketing campaigns beginning to ramp up and the improving economy, 2010 looks to be even more successful than our record year last year.”

There are five key areas to think about when to comes to cloud based data security. The first, and most obvious, is privileged user access. Processing and storage of data that is off site from the enterprise has inherint risk. With paper copies of documents and data, you can always keep track of their physical location. Passing off documents by hand ensures their safe arrival and that no one has accessed that data. The second issue is data location. While data is in the cloud, the files are still located on some server, somewhere in the world. While this might not seem like an issue, there are regulations on what data can be in a certain country. Also, since sensitive data might be mixed with non-sensitive data, its important that companies utilize some form of encryption for highly sensitive materials. Fourth, its important to have a backup plan. Disasters happen, and you want to make sure your cloud provider has a plan for when those do happen. Lastly, it’s important to have the flexibility to investigate potential foul behavior. It’s important for service providers to maintain the integrity of these systems by taking preventative and proactive measures.

Given the risks of cloud computing and cloud storage, PhysioGenix has developed a multi-leveled data security system to ensure that when customers utilize our data management system, their data is safe. Obvious front facing login security is made to prevent brute force attacks. There are additional security measures taken to ensure that only privileged users are able to access data. Once logged in and authenticated, sensitive documents are encrypted using AES 256 bit encryption. This is the highest level of encryption, and used by the US government for confidential documents. These systems allow PhysioGenix to provide our customers with data on demand, from anywhere in the world, while ensuring that their data is protected. Real time data is becoming a necessity in today’s business world, and PhysioGenix is leading it’s utilization in CRO data delivery. To find out more about PhysioGenix’s preclinical research services, email contact@physiogenix.com.

Matt worked at a leading data security company for two years, and now manages PhysioGenix’s website and internet presence. www.physiogenix.com

Today, I would like to talk about how “cloud computing” has accelerated and facilitated the viability of the FIPNet model.  If you have used Facebook, Linkedin, Salesforce, Google Apps. or other similar tools on the Internet, then you have used cloud computing.  “Cloud computing” in its broadest sense refers to the delivery of applications over the internet, which are accessed via a web browser; the data and software resides on remote servers.  At PhysioGenix, we have worked over the last year to move our IT infrastructure into the “cloud”.  This has created greater efficiencies, dramatically reduced costs and increased our delivery time of information to our clients.

The use of cloud computing allows partners within a FIPNet to share information, calendars, have web meetings (e.g., WebEx, GoToMeeting) and manage projects (e.g., Basecamp) anywhere in the world, as long as they have access to the Internet.  It doesn’t matter if one company is using Linux and the other is using Microsoft (or any other combination of client-side software/operating systems).

One of the current impediments to faster adoption of cloud computing is the security issue.  My colleague Matt will dive into the issue of security in our next post.

Lilly is certainly on the leading edge of executing partnership programs. In part because Lilly has a long history of using partnerships to build their pipeline. Remember the world’s first commercially available insulin product (Iletin) in 1923 was the result of a collaboration of Lilly and Frederick Banting and Charles Best, professors at the University of Toronto. Banting went on to win the Nobel Prize for his role in isolating and purifying insulin. Another large breakthrough in the treatment of diabetes was the partnership of Herbert Boyer, Founder of Genetech and Lilly to produce the first commercially available biosynthetic human insulin (Humulin) in 1982. Lilly can also point to more recent partnerships such as Galapagos and Piramal Life Sciences.

FIPNets provide enhanced productivity, expand capabilities, and increase access to assets. The multiple deal structures and decentralized management of FIPNets will increase logistical management. But with today’s technology and the benefits gained from a shared risk and reward model, we believe that the services provided by PhysioGenix are the ideal choice for businesses looking to outsource preclinical research. We are constantly striving to refine our processes and communication methods for our clients driving value into our “core competencies” within the global FIPNet model.

In a January 5, 2010 article in the Wall Street Journal, Jonathan Rockoff, wrote about Eli Lilly & Co.’s expanded use of outsourcing to run tests on its drug candidates.  Lilly has partnered with third-parties to develop a novel rheumatoid arthritis drug.  In adopting this approach, Rockoff said that,

At PhysioGenix, our core competencies are preclinical research in chronic diseases, in particular metabolic and neurological disorders, and the process and methodology for conducting such research.  From an outsourcing perspective, we have seen trends similar to those identified by Rockoff.  Large pharmaceutical and biotechnology companies have been seeking more extensive relationships, including risk and return sharing in the drug development process.

Outside of large biopharma, we have also seen a virtualization of the smaller early-stage biopharma companies.  They are running very lean organization and outsourcing almost every aspect of their business with their core competency being project management.  We believe that larger biopharma companies over time will come to more closely emulate the early-stage model; thereby, giving them access to the best practices in each competency and access to the best talent around the world.  This will result in faster, less expensive drug development.  My colleague Dr. Curry will talk about the expansion of this model in our blog post next week.

2010 promises to be a very interesting year for our industry with a continued acceleration of change in the drug development business model.